The global erectile dysfunction drugs market size was estimated at USD 2.71 billion in 2023 and is projected to grow at a CAGR of 9.0% from 2024 to 2030. The market is influenced by several factors, including a rising geriatric population, increasing R&D efforts, and a growing prevalence of erectile dysfunction (ED). For instance, In April 2024, The Journal of Sexual Medicine published an article stating that the prevalence of ED based on the International Index of Erectile Function (IIEF-5) scores was 24.2%. These trends highlight the significant market opportunities and challenges in the healthcare sector, particularly in areas related to aging demographics and advancements in medical research.
The increasing prevalence of ED is one of the key factors driving market growth over the forecast period. ED is a condition where men are unable to maintain a penile erection due to physical and psychological health issues, including diabetes, high cholesterol, smoking, stress, and mental health issues. According to a WHO report, approximately 15% of men are affected by ED each year, which is projected to reach 320 million by 2025.
ED is a highly prevalent condition in geriatric men. Natural decline in testosterone levels, reduced blood flow, and other age-related physiological changes contribute to the higher incidence of ED among older men. This disease significantly impacts a patient’s quality of life and healthcare resources. The geriatric population is more likely to have chronic conditions such as diabetes, cardiovascular disease, and hypertension, which are major risk factors for ED. According to the World Social Report 2023, the global population of individuals aged 65 and older is projected to more than double, increasing from 761 million in 2021 to 1.6 billion by 2050. Thus, the increasing geriatric population impels the prevalence of ED in men during the forecast period.
Technological advancement in drug delivery, the high burden of disease, and strong healthcare infrastructure are some factors driving market growth. Growing demand for robust pharmaceutical medicine to address the increase in ED prevalence is one of the key contributors to the growth in the adoption of ED medicines. Increasing investment in the R&D of novel drugs to treat patients with ED is expected to drive market growth. As per a recent research study published by Dove Express, in 2023, a significant rise in research studies on ED was recorded over the last 20 years. The leading countries in ED research include the UK, Italy, and the U.S. Recommendations focus on fostering interdisciplinary collaborations, exploring innovative therapeutic strategies, addressing psychological & relational aspects, conducting long-term studies, and publishing findings in reputable journals. Between 1971 and 2021, 16,114 research documents were published on ED, showing a growth rate of 5%.
The market is highly innovative. Recent advancements include developing novel drug delivery systems such as sublingual tablets, topical creams, and nasal sprays to enhance efficacy and patient convenience. The introduction of telemedicine services for online consultations and prescription refills revolutionizes access to treatment for individuals with erectile dysfunction. For instance, in September 2021, GoodRx launched GoodRx Health, which offers authoritative health information through GoodRx Answers, Health Wizards for decision-making, and expert videos.
The market has seen moderate merger and acquisition activity, with companies strategically acquiring or merging with others to expand their product portfolios and market reach. In February 2024, Zuellig Pharma, a prominent provider of healthcare solutions in Asia, finalized the purchase of two brands, Cialis (Tadalafil) and Alimta (Pemetrexed), from Eli Lilly and Company (“Lilly”) for specific ASEAN markets, which encompass Cambodia, Brunei, Laos, Malaysia, Indonesia, Myanmar, Thailand, and the Philippines. It was acquired through its wholly-owned subsidiary, Zanovex Pte. Ltd.
Regulatory factors significantly impact the market, influencing product approvals, pricing strategies, marketing practices, and market access. Recent regulatory developments include increased scrutiny of direct-to-consumer advertising of prescription medications for erectile dysfunction by regulatory bodies such as the FDA in the U.S. and the EMA in Europe. Stringent regulations regarding clinical trials and post-market surveillance raise compliance costs for pharmaceutical companies operating in this space.
The erectile dysfunction drugs industry is experiencing growth due to a shift towards developing combination therapies that target multiple aspects of erectile dysfunction simultaneously, such as addressing both physiological and psychological factors. The introduction of generic versions of popular erectile dysfunction drugs has expanded market accessibility and affordability for patients worldwide. For instance, Petros Pharmaceuticals secured USD 15 million through a private placement to advance STENDRA towards OTC status. Petros aimed to lead the OTC approval process for ED treatments.
Regional expansion efforts are ongoing at a moderate level in the market. Regional expansion is a critical aspect of growth strategies within the market, as companies aim to tap into emerging markets with high unmet medical needs and growing healthcare infrastructure. Market players are expanding their presence in Asia-Pacific and Latin America due to increasing awareness about sexual health issues and rising disposable incomes.
The Viagra (sildenafil citrate) segment held the largest market share of 57.47% in 2023. Viagra (sildenafil citrate) was the first Phosphodiesterase 5 (PDE5) inhibitor drug approved for Erectile Dysfunction (ED). This drug was developed and commercialized by Pfizer Inc. The patent for the branded version of Viagra expired in 2020, and therefore, to fill the demand gap in the market, Pfizer Inc. launched a generic version of Viagra at half the retail price-USD 65. A generic version of Viagra has been available in Canada and Europe since 2012 and 2013. There are strategic initiatives such as research collaboration, partnerships, and agreements undertaken by key local players to expand their business footprint
The other drugs segment is expected to grow at the fastest CAGR over the forecast period. Other medicines, such as Mirodenafil (Mvix), Helleva (lodenafil Carbonate), MAXON Forte, and Maxon Active, are also used to treat adult patients with ED. Helleva was developed by Cristalia and is prescribed to men suffering from ED. Initially, it was approved in Brazil. MAXON Forte and Maxon Active are OTC products of Adamed that are indicated for treating adult patients with ED. The approval of products for OTC sales is anticipated to fuel market growth. For instance, in February 2022, Adamed received a marketing authorization approval for Tadalafil MAXON from prescription to OTC category from the president of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products.
The oral mode of administration segment dominated the market in terms of revenue in 2023 with a market share of 84.15%. Oral Erectile Dysfunction (ED) medications, such as sildenafil (Viagra), tadalafil (Cialis), vardenafil (Levitra), and avanafil (Stendra), are highly effective in treating ED by enhancing blood flow to the penis, thereby facilitating erections in response to sexual stimulation. The rising preference for self-administration and home care services and increased investments in pharmaceutical research & development drive the market. Oral ED medications are effective for many men. In February 2023, Hims & Hers Health, Inc. introduced Hard Mints. These mint-flavored chewable tablets are designed to address erectile dysfunction and are available by prescription. They provide options for personalized dosages and contain active ingredients like Vardenafil and Tadalafil, similar to those found in Levitra, Staxyn, Cialis, and Viagra.
The other modes of administration segment is expected to witness the fastest CAGR over the forecast period. Other modes of administration include topical and intraurethral. The rising incidence of erectile dysfunction and growing awareness about new topical and intraurethral drugs are anticipated to boost market growth during the forecast period. Some of the available topical drugs for the treatment of ED are alprostadil cream (Vitaros), nitroglycerin-based ointments, and Eroxon. In June 2023, the U.S. FDA granted permission for Future Medical to market. OTC sells Eroxon medicine indicated to treat patients with ED in the U.S. Eroxon is a topical gel that offers an erection within 10 minutes compared to other drugs. Thus, the high safety and efficacy of the drug are anticipated to boost the demand for this topical gel for ED treatment over the forecast period.
North America erectile dysfunction drugs market dominated the market and accounted for a 50.93% share in 2023 due to the high burden of disease, robust healthcare infrastructure, and rapid approval of new products for treatment in the region. Sedentary lifestyles, stress, unhealthy dietary habits, and other lifestyle factors contribute to the prevalence of ED. Furthermore, Advances in medical technology have led to the development of more effective and convenient treatment options for ED. This has encouraged more individuals to seek treatment and has expanded the market for ED drugs. Moreover, the increasing prevalence of ED and the growing demand for personalized nutrition contribute to market growth. In June 2023, Haleon plc entered the US’s new OTC ED segment with an agreement for Futura Medical plc’s non-prescription MED3000 gel. They delivered USD 4 million to capitalize on Futura’s topical treatment. According to the terms of the agreement, Haleon will be accountable for all investments and actions related to the launch and marketing of the product in the country.
The erectile dysfunction drugs market in the U.S. is expected to grow over the forecast period. The U.S.market for erectile dysfunction drugs is driven by various factors, such as the high prevalence of ED, increasing awareness about available treatment options, technological advancements in drug development, and the presence of key pharmaceutical companies specializing in these medications In January 2024, Hims & Hers Health, Inc. partnered with Hartford HealthCare (HHC) to enhance access to in-person healthcare services. The collaboration allowed seamless referrals from Hims & Hers platform to HHC's extensive network for complex medical needs. It expanded Hims & Hers' reach across 14 states and Washington, D.C., supporting personalized treatments.
The erectile dysfunction drugs market in Europe was identified as a lucrative region in this industry. The increasing incidence of ED in Europe due to aging populations, lifestyle changes, and chronic diseases is a significant driver for market growth. Established healthcare infrastructure, increasing preference for personalized medication, and increased investments in pharmaceutical R&D are driving market growth. Companies launching new products further expand their market penetration in the region. For instance, in January 2024, sexual health pharmaceutical company Futura Medical extended its commercialization agreement with Cooper Consumer Health to commercialize its gel-based ED drug in Europe.
The UK erectile dysfunction drugs market is expected to grow over the forecast period. In the UK, ED is a common condition that affects many men, particularly those over the age of 40. It is estimated that around half of men between the ages of 40 and 70 in the UK experience some degree of ED. The condition can have various physical and psychological causes, including high blood pressure, diabetes, depression, anxiety, hormone imbalances, and lifestyle habits like smoking & excessive alcohol consumption. In January 2024, a survey on Erectile Dysfunction Statistics 2023 asked 1,000 UK men about their experiences with erectile dysfunction during sex. The results revealed that more than half (58.2%) of men in the UK face difficulties achieving an erection. Such a rising number of cases is anticipated to boost the UK market.
The erectile dysfunction drugs market in France is anticipated to grow over the forecast period. the regulatory environment in France supports access to safe and effective medications for treating ED. This favorable regulatory landscape encourages innovation and investment by pharmaceutical companies in developing new ED drugs.
Germany erectile dysfunction drugs market is expected to grow over the forecast period. According to a health study conducted on Bavarian men in September 2023, at least one sexual dysfunction was found in the volunteers involved in the study, among which 21% were affected with ED. Furthermore, key players like Pfizer, Lilly, and Bayer dominate the German ED drugs market.
The erectile dysfunction drugs market in Asia Pacific is anticipated to witness the fastest CAGR of 10.3% from 2024 to 2030. T A significant rise in the prevalence of diabetes in the region over the last decade is likely to result in a higher incidence of diabetes-related erectile disorders. In addition, the increasing prevalence of mental illnesses drives market growth. Psychological disorders can lead to psychogenic ED, leading to an increased demand for ED drugs. According to a study published in Nature in March 2024, the prevalence of mental disorders in Asian countries in the past three decades has increased from 43.9 million to 69.0 million.
China erectile dysfunction drugs market is expected to grow over the forecast period. Continuous innovation in the pharmaceutical industry, including the development of new and more effective ED drugs, contributes to the expansion of the market in China. The country's increasing geriatric population plays a significant role in driving the demand for ED medications due to age-related physiological changes.
The erectile dysfunction drugs market in Japan is anticipated to grow at a significant CAGR over the forecast period. Japan has one of the oldest populations globally, with a significant proportion of elderly individuals. As people age, they are more likely to experience conditions such as ED due to physiological changes. Japan’s established healthcare infrastructure ensures that individuals can access quality medical care, including treatments for conditions like ED.
India erectile dysfunction drugs market is anticipated to grow at a rapid rate over the forecast period. The aging population in India is experiencing an increase in the prevalence of ED, similar to global trends. Physiological changes that occur with aging contribute to the development of ED, leading to a greater need for medications that can address these issues.
The erectile dysfunction drugs market in the Middle East and Africa is projected to grow in thenear future due to the rise of conditions such as diabetes, cardiovascular diseases, obesity, and hypertension, all of which are risk factors for ED. Diabetes is recognized as a silent killer in the African continent. Furthermore, the region's launch and approval of new drug formulations impact market growth. For instance, in August 2023, Labatec Pharma obtained regulatory approval to distribute Futura Medical's gel-based topical medicine in Saudi Arabia.
Saudi Arabia erectile dysfunction drugs market is expected to grow over the forecast period. The advancement of healthcare infrastructure in Saudi Arabia has enhanced accessibility to medical care and treatment for erectile dysfunction. The rise in disposable income among Saudis has enabled more individuals to afford costly treatments for ED, thus contributing to the market's growth.
The erectile dysfunction drugs market in Kuwait is anticipated to witness growth over the forecast period. The healthcare infrastructure in Kuwait has improved over the years, with better access to healthcare services and facilities. This has facilitated easier access to diagnosis and treatment for conditions like erectile dysfunction, contributing to the growth of the ED drugs market.
Key players operating in the market are undertaking various initiatives to strengthen their market presence and increase the reach of their products and services. Strategies such as expansion activities and partnerships play a key role in propelling market growth.
The following are the leading companies in the erectile dysfunction drugs market. These companies collectively hold the largest market share and dictate industry trends.
In May 2024, Petros Pharmaceuticals and 23andMe partnered with Lemonaid Health, a subsidiary of 23andMe, to offer all strengths of STENDRA (avanafil) for ED on Lemonaid's telehealth platform. This collaboration aimed to enhance access to STENDRA nationwide, increase brand awareness, and support Petros' goal to switch STENDRA to OTC status, potentially pending FDA approval.
In February 2024, Petros Pharmaceuticals and 23andMe partnered with a major AI software provider to integrate advanced technology into its Self-Selection Study for STENDRA (avanafil) OTC approval. The AI-driven tool aimed to improve screening accuracy, ensure safe access to medication under FDA & ACNU guidelines, and enhance Petros' pathway toward OTC status.
In May 2023, Hims & Hers Health, Inc. launched Hard Mints, chewable mint-flavored tablets for treating sexual dysfunction, in the U.S. They will be available in the UK starting in June. Leveraging active ingredients such as Viagra, Cialis, & Levitra, they aim to offer a personalized and discreet solution backed by positive customer feedback and facilitated through their telehealth platform
Report Attribute |
Details |
Market size value in 2024 |
USD 2.92 billion |
Revenue forecast in 2030 |
USD 4.90 billion |
Growth rate |
CAGR of 9.0% from 2024 to 2030 |
Actual data |
2018 - 2023 |
Forecast period |
2024 - 2030 |
Quantitative units |
Revenue in USD million/billion and CAGR from 2024 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Product, route of administration, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; Mexico; Germany; UK; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; South Korea; Australia; Thailand; Brazil; Argentina; South Africa; Saudi Arabia; UAE; Kuwait |
Key companies profiled |
Bayer AG; Lilly; GSK plc.; Petros Pharmaceuticals, Inc.; Pfizer Inc.; Teva Pharmaceutical; Industries Ltd; Lupin Limited; Futura Medical; Cure Pharmaceutical; 23andMe (Lemonaid Health); Hims & Hers Health, Inc.; Ro; BlueChew; GoodRx, Inc. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global erectile dysfunction drugs market report based on product, route of administration, and region:
Product Outlook (Revenue, USD Million, 2018 - 2030)
Viagra (sildenafil citrate)
Cialis (Tadalafil)
Levitra/Staxyn (vardenafil)
Stendra/Spedra (avanafil)
Zydena (udenafil)
Other Drugs
Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
Oral Mode of Administration
Injectable Mode of Administration
Other Modes of Administration
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
China
Japan
India
South Korea
Australia
Thailand
Latin America
Brazil
Argentina
MEA
South Africa
Saudi Arabia
UAE
Kuwait
b. The global erectile dysfunction drugs market size was estimated at USD 2.71 billion in 2023 and is expected to reach USD 2.92 billion in 2024.
b. The global erectile dysfunction drugs market is expected to witness a compound annual growth rate of 9.0% from 2024 to 2030 to reach USD 4.90 billion in 2030.
b. Based on products, the viagra segment held the largest share of 57.47% in 2023, owing to the increasing focus of various companies on commercializing generic products in order to expand their product portfolio
b. Some key players operating in the erectile dysfunction drugs market include Pfizer, Inc.; Eli Lilly and Company; Teva Pharmaceutical Industries Ltd; Sanofi; Sun Pharmaceutical Industries Ltd; Bayer AG; Petros Pharmaceuticals, Inc., VIVUS, Inc., Auxilium Pharmaceuticals, Inc., and Adamed among others
b. Key factors driving the erectile dysfunction drugs market growth include increasing disease burden of ED, increasing product approval & launches, and supportive reimbursement policies.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."